NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference

Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023CAMBRIDGE, Mass., Se...

Related Keywords

Phoenix ,Arizona ,United States ,University Of Arizona ,Cambridge ,Cambridgeshire ,United Kingdom ,San Francisco ,California ,American ,Jeremy Shefner ,Cantor Fitzgerald ,Gregoryw Fulton ,Charles Duncan ,Clinical Trials Consortium ,Linkedin ,Department Of Neurology ,Twitter ,Barrow Neurological Institute ,Drug Administration ,Cantor Healthcare Team ,Nasdaq ,Neurosense Therapeutics Ltd ,Neuromuscular Disease Center ,European Medicines Agency ,Neurosense Therapeutics ,Cantor Neurology ,Psychiatry Conference ,New Treatment Paradigm ,Scientific Advisory Board ,Keynote Speaker ,Disease Center ,Executive Chair ,American Board ,Trials Consortium ,Editorial Boards ,Managing Director ,Orphan Drug Designation ,Sense Therapeutics ,Neurosense Therapeutic ,